Efeito da oxigenoterapia hiperbárica na lesão por isquemia reperfusão intestinal by DANIEL, Rosemary Aparecida Furlan et al.
Acta Cirúrgica Brasileira - Vol. 26 (6) 2011 - 463
10 – ORIGINAL ARTICLE
Ischemia/Reperfusion
Effect of hyperbaric oxygen therapy on the intestinal ischemia reperfusion injury1
Efeito da oxigenoterapia hiperbárica na lesão por isquemia reperfusão intestinal 
Rosemary Aparecida Furlan DanielI, Vinícius Kannen CardosoII, Emanuel Góis JrIII, Rogério Serafim ParraIV, Sérgio Britto 
GarciaV, José Joaquim Ribeiro da RochaVI, Omar FéresVII
IFellow Master degree, Department of Surgery and Anatomy, FMRP-USP, Ribeirao Preto-SP, Brazil. Main author, responsible for manuscript 
preparation.
IIBiomedical, Fellow Master degree, Department of Forensic Medicine and Pathology, Experimental Pathology Section of Cancer Biology, FMRP-
USP, Ribeirao Preto-SP, Brazil. Involved with technical procedures.
IIIFellow Master degree, Department of Surgery and Anatomy, FMRP-USP, Ribeirao Preto-SP, Brazil. Responsible for English language.
IVFellow Master degree, Department of Surgery and Anatomy, FMRP-USP, Ribeirao Preto-SP, Brazil. Responsible for manuscript preparation and 
critical revision.
VPhD, Full Professor and Head of the Department of Forensic Medicine and Pathology, Experimental Pathology Section of Cancer Biology, FMRP-
USP, Ribeirao Preto-SP, Brazil. Responsible for intellectual and scientific content of the study.
VIPhD, Full Professor and Head of Division of Coloproctology, Department of Surgery and Anatomy, FMRP-USP, Ribeirao Preto-SP, Brazil. Responsible 
for intellectual and scientific content of the study, critical revision.
VIIPhD, Associate Professor, Department of Surgery and Anatomy, FMRP-USP, Ribeirao Preto-SP, Brazil. Responsible for intellectual and scientific 
content of the study, critical revision.
ABSTRACT
PURPOSE: Adequate tissue oxygenation is essential for healing. Hyperbaric oxygen therapy (HBOT) has potential clinical applications 
to treat ischemic pathologies, however the exact nature of any protective effects are unclear at present. We therefore investigated the 
potential role of HBOT in modulating the ischemia/reperfusion (I/R) injury response in intestinal model of I/R injury.
METHODS: Male Wistar rats were subjected to surgery for the induction of intestinal ischemia followed by reperfusion. HBOT 
was provided before and/or after intestinal ischemia. Cell viability in the intestinal tissue was assessed using the MTT assay and by 
measuring serum malondealdehyde (MDA). Microvascular density and apoptosis were evaluated by immunohistochemistry.
RESULTS: The results indicate that HBOT treatment pre- and post-ischemia reduces lesion size to the intestinal tissue. This treatment 
increases cell viability and reduces the activation of caspase-3, which is associated with increased number of tissue CD34 cells and 
enhanced VEGF expression. 
CONCLUSION: The hyperbaric oxygen therapy can limit tissue damage due to ischemia/reperfusion injury, by inducing reparative 
signaling pathways.
Keywords: Reperfusion Injury. Hyperbaric Oxygenation. Rats.
RESUMO
OBJETIVO: Oxigenação tissular adequada é essencial para cicatrização. Oxigenoterapia hiperbárica (HBOT) tem aplicação clínica 
para tratar lesões isquêmicas, entretanto a natureza exata dos mecanismos envolvidos permanece incerta. Procuramos investigar o papel 
potencial da HBOT na modulação da resposta a uma lesão por isquemia reperfusão (I/R) intestinal em modelo de lesão de I/R.
MÉTODOS: Ratos machos Wistar foram submetidos à cirurgia para a indução da isquemia intestinal seguida de reperfusão. HBOT foi 
fornecido antes e / ou após a isquemia intestinal. A viabilidade das células no tecido intestinal foi avaliada através do ensaio de MTT e 
pela medição malondealdeido (MDA) no plasma. Densidade microvascular e apoptose foram avaliados por imuno-histoquímica.
RESULTADOS: Os resultados indicam que o tratamento HBOT pré e pós-isquemia reduz o tamanho da lesão ao tecido intestinal. Este 
tratamento aumenta a viabilidade celular e reduz a ativação da caspase-3, que está associada com aumento do número de células CD 
34 no tecido e da expressão da VEGF. 
CONCLUSÃO: A oxigenoterapia hiperbárica pode limitar os danos do tecido devido à lesão por isquemia/reperfusão, induzindo às 
vias de sinalização reparadora.
Descritores: Traumatismo por Reperfusão. Oxigenação Hiperbárica. Ratos.
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Introduction
The relationship between mesenteric ischemia and 
the action of free radicals during the reperfusion period is well 
established, with tissue damage largely occurring due to reperfusion 
injury rather than the initial ischemic insult. Hyperbaric oxygen 
therapy (HBOT) has been employed in various clinical situations, 
including wounds, carbon monoxide poisoning, necrotizing soft 
tissue infection, and osteoradionecrosis. However, HBOT has 
not been systematically used in organ transplantation, despite the 
frequency of ischemia and reperfusion experienced by patients 
during this procedure. Current knowledge indicates that HBOT 
increases the O2 concentration in tissues with impaired blood 
supply1 and diminishes the inflammatory process by interfering 
with the production and the activity of cytokines. Additionally, 
HBOT stimulates wound healing, angiogenesis and osteogenesis, 
thereby elevating antioxidant enzyme levels and relieving tissue 
hypoxia2.
Vascular endothelial growth factor (VEGF) is a key 
signaling protein that induces neovascularization during tissue 
repair. Oxygen tension is a key regulator of VEGF expression both 
in vitro and in vivo, with hypoxia a potent inducer of VEGF. More 
recently, hyberbaric oxygen has also been demonstrated to induce 
VEGF formation3. The expression of VEGF is related to the 
expression of the CD34+ antigen, which induces the expression 
of endothelial progenitor cells (EPCs) of both hematopoietic and 
vascular origin4. CD34+ cells are detected in newly formed blood 
vessels under pathological conditions and are associated with the 
accelerated restoration of blood flow5. Because of the association 
of VEGF and CD34+ expression with neovascularization and the 
restoration of blood flow, they are appropriate markers for tracking 
the role of HBOT in improving the outcomes associated with 
ischemia and reperfusion. The aim of this work is to explore this 
process in a rat model of bowel surgery.
Methods
This work was approved by the Institutional Research 
Ethics Committee. Thirty Wistar rats weighing 300-400g were 
provided by the animal housing facilities of the institution and were 
maintained in metal cages at a temperature of 24°C. The animals 
were treated according to the instructions of the Committee with 
regard to laboratory handling and care.
Experimental design
The rats were randomly distributed into five groups of six 
animals each. The first group was designated the Control group. 
Animals of the second group (I-R) were subjected to surgery-
induced ischemia/reperfusion; the rats in the third group (I-R/
HBOT) received the surgery followed by HBOT; the fourth group 
(HBOT/I-R/HBOT) was treated with HBOT before and after the 
surgical procedure, and the fifth group (HBOT/I-R) was treated 
with HBOT prior to surgery but not afterwards.
Surgical procedure
The animals were anesthetized by intraperitoneal 
injection of 1.0g Thiopentax (sodium thiopental – Cristália; 
dosage = 50 mg/kg). Intestinal ischemia was achieved by 
occluding the superior mesenteric artery for sixty minutes 
using a microvascular clamp6. The occurrence of ischemia was 
recognized by the presence of pale intestinal loops that lacked a 
pulse (Figure 1). The abdominal cavity was temporarily closed by 
means of a continuous suture. After sixty minutes of ischemia, the 
cavity was reopened, the microvascular clamp was removed, and 
reperfusion was initiated (3h). Reperfusion was identified by the 
return of a pulse and by the restoration of the pink coloration of the 
intestine. All of the animals were euthanized after three hours of 
reperfusion. Animals in the control group were anesthetized, and 
their abdominal cavities were opened, but they were not subjected 
to ischemia/reperfusion.
FIGURE 1 - Pale intestinal loops following the placement of the 
microvascular clamp – Beginning of ischemia
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HBOT treatment
The animals were placed in an experimental hyperbaric 
chamber for the application of HBOT. Each HBOT session lasted 
two hours, i.e., fifteen minutes of pressurization of up to 2 ATA and 
the maintenance of this pressure for ninety minutes, followed by 
fifteen minutes of depressurization.
Sample collection and euthanasia
At the end of the experiment, the abdominal cavity was 
reopened and 20 cm of the intestine was removed. The first 10-cm 
section was used for the methyl thiazolyl blue (MTT) assay, while 
the remaining 10-cm section was fixed in 10% formalin solution in 
preparation for histological and immunohistochemical evaluation. 
Blood samples were collected using vacuum tubes (Vacutainer) 
containing EDTA for the determination of malondealdehyde 
(MDA) plasma levels. Following sample collection, the animals 
received an extreme dose of anesthetics that culminated in 
cardiorespiratory arrest.
Biochemical analysis - MTT and MDA
For MTT analysis, intestinal samples were collected in 
Eppendorf tubes (1.5 mL) with 550 µL PBS and 5.5 µL MTT (5mg/
mL, Sigma), which was incubated at 37°C for two hours. Next, 
400 µL of isopropyl acid (HCl 0.004 N propanol) was added, and 
the resulting solution was incubated at room temperature for five 
minutes, followed by homogenization. The analysis was repeated 
five times for each animal, and the results were obtained using 
a spectrophotometer (ZEISS, SPEKOL 1,100) at a calibrated 
wavelength of 570 nm. The results are expressed as absorbance.
MDA levels were determined by means of the TBAR 
technique (thiobarbituric acid reactive substances). MDA reacts 
with thiobarbituric acid to give a fluorescent pink chromogen that 
absorbs at 532 nm and emits fluorescence at 553 nm7,8.
Histopathological evaluation
The intestine samples were fixed according to standard 
procedures8.
Mucosal lesions were examined by two independent 
pathologists and classified according to the method developed by 
Chiu on the basis of hematoxylin-eosin staining9.
Immunohistochemical analysis
Immunohistochemical reactions were performed on 
the histological sections prepared on paraffin by means of an 
antigen-antibody reaction followed by detection with a marker and 
observation under a microscope. The slides were treated with the 
primary antibody cysteine protease protein (CPP)-32-caspase-3, 
clone JHM62, diluted 1:300 for twelve hours and incubated in a 
humidified chamber, at which time the antibody reacted with the 
antigen, forming an immunocomplex. For staining of the VEGF 
and CD34+ cells, the following specific antibodies were utilized: 
VEGF-NCL-L-VEGFR-3 (clone KLT9; 1:200) and CD34+-NCL-
END-CD34 (clone QBEnd/10; 1:100).
Statistical analysis
The data were analyzed using the program GraphPad 
Prism 5 (Graph Pad Software In., San Diego, California, USA). 
The Kolmogorov-Smirnov test was applied to verify the normal 
distribution of the data. In the case of normal distribution, One-
way ANOVA and Tukey post-test were performed. Significance 
was set at p<0.05.
Results
The histopathological evaluation and classification of 
the lesions detected in the experimental groups and the control 
animals is summarized in Table 1, using the criteria proposed by 
Chiu. To evaluate the effect of HBOT on intestinal I/R injury and 
lesion formation, we used the well described rat mesenteric model 
of I/R. No lesions were detected in the mucosa of the Control 
animals, whereas the I-R group presented grade 5 tissue injuries, 
characterized by the loss of the villi. In the I-R/HBOT group, 
the lesions were categorized as grades 4 and 5, with epithelium-
denuded villi. For the the HBOT/I-R/HBOT group, grade 2 lesions 
were observed (i.e., extended sub-epithelial spaces between the 
villi and visible cell lysis). Grade 3 and 4 lesions were observed 
in the HBOT/I-R group, with significant epithelial lifting down 
the sides of the villi. Taken together, HBOT prior to ischemia 
reperfusion (HBOT/I-R/HBOT and HBOT/I-R groups) limited 
injury to the intestinal mucosa.
TABLE 1 – Classification of the mucosa lesions detected 
in the experimental animals according to Chiu9
Group
Animals 
Control
group
   I-R
 group
HBO/I-R
 group
HBO/I-R/HBO 
group
I-R/HBO
group
1 grade 0 grade 5 grade 3 grade 3 grade 4
2 grade 0 grade 5 grade 3 grade 2 grade 4
3 grade 0 grade 5 grade 3 grade 2 grade 4
4 grade 0 grade 5 grade 3 grade 2 grade 4
5 grade 0 grade 5 grade 4 grade 2 grade 4
6 grade 0 grade 5 grade 3 grade 2 grade 5
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There was a significant increase in the MTT levels in 
the groups treated with HBOT (HBOT/I-R, HBOT/I-R/HBOT) 
(Figure 1), demonstrating increased cell viability in these groups. 
Additionally, reduced MDA levels were detected in the HBOT/
I-R/HBOT group (Figure 2) compared with the groups without 
HBOT (p<0.05; p<0.01).
FIGURES 1 and 2 - Analysis of the results from the MTT assays and 
MDA determinations in the experimental and Control groups. There are 
significant differences among the groups 
Examination of the expression of CD34+ and VEGF 
levels in the HBOT/I-R/HBOT group compared with the other 
groups (Control, I-R, HBOT/I-R, I-R/HBOT) (p<0.01; p<0.001) 
revealed a significant elevation of both CD34+ and VEGF (Figures 
3 and 4). VEGF expression in the HBOT/I-R/HBOT group was 
significantly elevated compared with the HBOT/I-R (p<0.001) 
and I-R/HBOT (p<0.01) groups. The expression of VEGF was 
similar to that of CD34+ (p<0.01; p<0.001, respectively) for both 
I-R and I-R/HBOT groups (Figures 5 and 6).
FIGURE 3 - Immunohistochemical analysis of the HBO /I-R/HBO group
V- vilosity, M- mucosa, S- serosa,     - CD34+ markers   
FIGURE 4 - Immunohistochemical analysis of the HBO/I-R/HBO group. 
M- mucosa, S- serosa, - VEGF markers
S
M
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FIGURES 5 and 6 - Results from the CD34+ and VEGF determination 
in the experimental and Control groups. There are significant differences 
among the groups.
We also examined cytosolic caspase 3 in the intestinal 
mucosa (Figure 7). There was a significant decrease in the levels 
of caspase-3 expression in the HBOT/I-R/HBOT group compared 
with the groups without HBOT (Figure 8).
FIGURE 7 - Immunohistochemical aspect of caspase-3 in the HBO/I-R/
HBO group. 
V - villosity,-  caspase-3 markers
FIGURE 8 - Caspase-3 expression levels in the experimental and Control 
groups. The best result was achieved for the HBO/I-R/HBO group, with 
statistical significance.
Discussion
HBOT enhances oxygen concentration in tissues 
stimulating angiogenesis10 and led to a reduction in tissue damage. 
Additionally, a decreased number of inflammatory cells were 
detected in the ischemic intestinal mucosa, in accordance with 
recent studies indicating that HBOT therapy may diminish the 
inflammatory response10,11. In our experimental model, there was 
an attenuated inflammatory response due to HBOT treatment 
and a maintenance of the intestinal mucosa following ischemia-
reperfusion injury.
In the current study, immunohistochemical analysis 
revealed that both the HBOT/I-R/HBOT and the HBOT/I-R 
treatment group led to an increase in VEGF and CD34+ cells. 
Studies of in vitro ischemia have shown VEGF expression is 
the key regulator of enhanced vascular and endothelial cell 
permeability11,12 and hypoxia maintains the characteristics of 
CD34+ cells by decreasing intracellular levels of reactive oxygen 
species13. However, in the case of the HBOT/I-R/HBOT and 
HBOT/I-R groups, there was a significant rise in the number of 
tissue CD34+ cells. These findings are in agreement with previous 
human studies which demonstrated an increase in the population 
of CD34+ cells in the peripheral circulation in response to 
HBOT exposure for two hours14. Additionally, HBOT is known 
to stimulate stem/progenitor cell mobilization from the bone 
marrow, thereby accelerating the growth of vascular channels and 
stimulating vasculogenic mediators15.
It is likely that the effects of HBOT on intestinal ischemic 
tissues are similar to its effect on cardiac ischemic tissues. In 
the latter case, hypoxic-ischemic pre-conditioning induces a 
significant increase in the level of CD34+ cells in the peripheral 
blood. This protective effect is facilitated by the mobilization of 
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circulating progenitor cells, which improve cardiac contractility 
and ameliorate the ischemic injury16,17. Previous studies have 
indicated that HBOT exerts multiple actions on a variety of 
cellular pathways and functions, including apoptotic genes18, 
neuroprotection, decreased mortality and diminished ischemic 
cellular damage19,10. Here, we demonstrate a significant rise in the 
expression of caspase-3 in the I-R group, corroborating previous 
results21. HBOT therapy before and after I-R was associated with 
a significant decrease in the expression of caspase-3, concomitant 
with decreased cellular damage, as detected in the histological 
evaluation (grade 2). In accordance with our findings pre-
conditioning with HBOT has previously been shown to increase 
survival and suppress activity of caspase-3 and caspase-922. There 
is a relationship between the effect of HBOT on I-R injury in the 
bowels and apoptotic injury in the mucosa22. Early treatment with 
HBOT has a beneficial effect on ischemia23. These parameters 
may also be associated with increased VEGF expression. The 
evidence is clear that VEGF is anti-apoptotic agent and enhanced 
angiogenesis24. HBOT promotes tissue preservation with reduced 
apoptosis because it diminishes the levels of superoxide and 
hydrogen peroxide, resulting in a subsequent reduction in the 
amount of cytochrome c in the cytosol25. Indeed, Nylander et al.26 
have observed improved mitochondrial function associated with 
HBOT.
An increase in MTT levels, indicitive of cell health were 
observed in the HBOT/I-R/ HBOT and HBOT/I-R groups.  We 
speculate that enhanced VEGF expression induced by HBOT 
may lead to an increase in capillary density or vasodilation, thus 
promoting tissue oxygenation27. This re-establishment of tissue 
function is further supported by the MDA results, which revealed 
a low level of lipid peroxidation in the HBOT/I-R/HBOT group, 
as described previously28,29.
HBOT treatment has been shown to attenuate pro-
inflammatory cytokine release in response to potent inflammatory 
stimulus lipopolysaccharide (LPS)30,31. HBOT pre-conditioning 
is also associated with a decrease in nervous tissue injury, lower 
mortality, recovery of neurological function, reduced MDA levels, 
and increased antioxidant activity22,32. In this work, we have 
extended these findings to include a role for HBOT as a protective 
stimulus that limits tissue damage in response to intestinal ischemia 
and reperfusion. We suggest further investigation to determine if 
HBOT can be applied clinically as an adjuvant therapy for tissue 
damage occurring due to vessel ligation in organ transplantation.
Conclusion
The hyperbaric oxygen therapy can limit tissue damage 
due to ischemia/reperfusion injury, by inducing reparative 
signaling pathways.
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